期刊文献+

NMP22联合尿脱落细胞学检测在膀胱癌术后复发监测中的价值 被引量:3

The Value of Urinary Nuclear Matrix Protein 22 and Urine Cytology in the Diagnosis of Postoperative Recurrence of Bladder Cancer
原文传递
导出
摘要 目的:探讨尿核基质蛋白22(NMP22)联合尿脱落细胞学榆测对膀胱移行细胞癌诊断及术后复发监测中的应用价值。方法:采用酶联免疫法(EI。ISA)检测60例膀胱癌者、20例非膀胱癌者、20例健康志愿者尿中NMP22水平,并同时行尿脱落细胞学检查,并对结果进行比较。结果:膀胱癌者NMP22平均为35.6×10^3U/L,高于非膀胱癌者(7.8×10^3U/L)和健康志愿者(7.2×10^3U/L,P〈0.05);膀胱癌复发患者(31.5×10^3U/L)高于未复发患者(8.O×10^3U/L,P〈0.05);膀胱癌者NMP22的敏感性高于尿脱落细胞学,而其特异性低于尿脱落细胞学。结论:尿NMP22对膀胱移行细胞癌具有高灵敏度和无创伤性,是检测膀胱移行细胞癌的有效标志物;联合尿细胞学检查可进一步提高膀胱癌术后复发的诊断率。 Objective:To evaluate the value of urinary nuclear matrix protein 22 (NMP22) and urine cytology in the diagnosis of bladder transitional cell carcinoma and postoperative recurrence of bladder cancer. Methods: Urinary NMP22 levels were detected in 60 cases of bladder cancer, 20 cases of urinary non bladder cancer disease, 20 cases of healthy volunteers using enzyme-linked immunosorbent assay (ELISA), and urine cytology were detected at the same time, and the results were compared. Results:The average NMP22 of bladder cancer group was 35.6×10^3U/L, significantly higher than the non bladder cancer, urinary tract diseases group (7.8×10^3U/L) and healthy volunteers group (7.2×10^3U/L, P〈0. 05); recurrence of bladder cancer group cases (31.5×10^3U/L) was higher than patients with no recurrence (8.0×10^3U/L, P〈0.05). In bladder cancer group, the sensitivity of NMP22 is higher than urine cytology, and its specific is Lower than urine cytology. Conclusions:The detection of urinary NMP22 is highly sensitive and non-invasive to bladder transitional ceil carcinoma, It can be used as an effective marker in detection of bladder transitional cell carcinoma, urine cytology can be combined to further improve the diagnosis of postoperative recurrence of bladder cancer.
出处 《临床泌尿外科杂志》 北大核心 2009年第12期911-913,共3页 Journal of Clinical Urology
关键词 膀胱肿瘤 移行细胞癌 核基质蛋白22 尿细胞学 bladder tumor transitional cell earcinoma nuclear matrix protein 22 urine cytology
  • 相关文献

参考文献8

  • 1Droller M J. Evaluation of the clinical value of urinary NMP22 as a maker for screening and surveillance of transitional cell carcinoma of the urinary bladder [J]. J Urol, 2002, 168(2) :857-858.
  • 2朴永锋,刘鹏,朴春南.NMP22在膀胱癌诊断中的研究进展[J].肿瘤学杂志,2008,14(2):154-156. 被引量:3
  • 3Keesee S K, Briggman J V, Thill C, et al. Utilization of nuclear matrix proteins for cancer diagnosis[J]. Crit Rev Eukaryot Gene Expr, 1996,6(2):189-214.
  • 4Carpinito G A, Stadler W M, Briggman J V, et al. Urinary nuclear matrix proteinas a marker for transitional cell carcinoma of the urinary tract[J]. J Urol, 1996, 156(4) : 1280-1285.
  • 5Sanchez-carbayo M, Urrutia M, Silva J M, et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA21 - 1 and NMP22 for evaluating sympotomatic patients at risk for bladder cancer[J]. J Urol, 2001,165 (5):1462-1467.
  • 6Kibar Y, Goktas S, Kilic S, etal. Prognostic value of cytology, nuclear matrix protein 22(NMP22) test, and urinary bladder cancer Ⅱ (UBC Ⅱ) test in early recurrent transitional cell carcinoma of the bladder[J]. Ann Clin Lab Sci. 2006,36(1):31-38.
  • 7Soloway M S, Briggman J V, Carpinito G A, et al. Use of a new tumor marker,Urinary NMP22 ,in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[J]. J Urol, 1996, 159:363-367.
  • 8何朝宏,肖传国,杜茂信.尿核基质蛋白22在膀胱癌术后复发监测中的应用[J].临床泌尿外科杂志,2005,20(2):107-108. 被引量:3

二级参考文献31

  • 1邵晋凯,黄立坤,冯贵生,问晓东,曹金红.NMP22在膀胱癌早期诊断中的临床研究[J].中华泌尿外科杂志,2006,27(S1):48-49. 被引量:7
  • 2徐战平,戴宇平,赵继宗,邹伟民,王行环,杨浣情.膀胱移行细胞癌患者尿核基质蛋白22检测的意义[J].中华检验医学杂志,2005,28(2):192-192. 被引量:2
  • 3马利民,张跃平,张芹,周树军,王惠民.尿核基质蛋白检测在膀胱癌诊断中的应用价值评定[J].临床泌尿外科杂志,2005,20(3):175-177. 被引量:4
  • 4魏学斌,李青,赵庆利,门同义,李博,徐祗顺.尿NMP_(22)检测诊断膀胱癌的价值[J].山东医药,2005,45(9):12-13. 被引量:1
  • 5Ramakumar S, Bhuiyan J, Besse J A, et al. Comparison of screening methods in the detection of bladder cancer. J Urol,1999,161:388-394.
  • 6Soloway M S,Briggman J V,Carpinito G A,et al.Use of a new tumor marker, urinary NMP22,in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol,1996,159:363-367.
  • 7Landis S K, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin,1998,48:6-29.
  • 8Getzenberg R H,Konety B R,Oeler T A,et al.Bladder cancer associated nuclear matrix proteins.Cancer Res,1996,56:1690-1694.
  • 9Keesee K,Brigman J V,Thill G,et al.Utilization of nuclear matrix proteins for cancer diagnosis.CRC Crit Eukaryotic Gene Exp,1996,6:189-214.
  • 10Lyderson BK, Pettojohn DE. Human-specific nuclear protein that associates with the polar region of the mitotic apparatus: distribution in a human/hamster hybrid cell [J]. Cell, 1980, 22(2 Pt 2):489-499.

共引文献4

同被引文献20

  • 1何朝宏,肖传国,杜茂信.尿核基质蛋白22在膀胱癌术后复发监测中的应用[J].临床泌尿外科杂志,2005,20(2):107-108. 被引量:3
  • 2沈周俊,胡明明.膀胱癌尿液肿瘤标志物的研究和应用现状[J].临床外科杂志,2009,17(11). 被引量:8
  • 3Ecke TH. Focus on urinary bladder cancer markers: a review[J]. Minerva Urol Nefrol, 2008, 60(4) : 237-246.
  • 4Jemal A, Siegel R, Xu J, et al. Cancer statistics,2010[J]. CA Cancer J Clin, 2010, 60(5) : 277-300.
  • 5Soloway MS, Briggman V, Carpinito GA, et al. Use of a new mark- er, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[J]. J Urol, 1996, 156(21 Pt) : 363-367.
  • 6Ann JS, Kim HS, Chang SG, et al. The clinical usefulness of nu- clear matrix protein-22 in patients with atypical arine cytology [ J]. Korean J Urol, 2011, 52(9) : 603-605.
  • 7Arora VK, Sarungbam J, Bhatia A, et al. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carci- noma[J]. Diagn Cytopathol, 2010, 38(11) : 788-790.
  • 8Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear ma- trix proteins for cancer diagnosis [ J ]. Crit RevEukayotic Gene Expr, 1996, 6(2/3): 189-214.
  • 9Sharmat S, Zippe CD, Pandrangi I, et al. Exclusion criteria en- hance the specificity and positive predictive value of NMP22 and BTAstat[J]. JUrol, 1999, 162(1): 53-57.
  • 10黄翔,邹建华,廖勇,龚百生,符本琪,屈艺.尿液中核基质蛋白22联合端粒酶活性检测在膀胱癌诊断中的作用[J].现代泌尿生殖肿瘤杂志,2009,1(4):234-236. 被引量:3

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部